Key result
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers do not decrease mortality or hospitalization risk in patients with heart failure and preserved ejection fraction.
Why the study?
Do angiotensin-converting enzyme inhibitors or angiotensin receptor blockers reduce mortality or hospitalization risk in patients with heart failure with preserved ejection fraction?
Meta-Analysis (n=8,226)
Do angiotensin-converting enzyme inhibitors or angiotensin receptor blockers reduce mortality or hospitalization risk in patients with heart failure with preserved ejection fraction?
ACEI and ARB do not appear to provide a mortality or hospitalization benefit in patients with heart failure with preserved ejection fraction.
Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) constitute first line treatment for patients with heart failure with reduced ejection fraction. However, their role in patients with preserved ejection fraction remains controversial. Searching in Epistemonikos database, which is maintained by screening 30 databases, we identified five systematic reviews including five randomized trials. We combined the evidence using meta-analysis and generated a summary of findings table following the GRADE approach. We concluded ACEI and ARB do not decrease mortality or hospitalization risk in this group of patients.
No takes yet. Share an insight, caveat, or question.
Rain et al. (2015) conducted a meta-analysis in Heart failure with preserved ejection fraction (n=8,226). Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) vs. Placebo or standard treatment was evaluated on All-cause mortality and hospitalization. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers do not decrease mortality or hospitalization risk in patients with heart failure and preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: